COMMENTARY

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Amitriptyline Hydrochloride

R.H. MANZO,1 M.E. OLIVERA,1 G.L. AMIDON,2 V.P. SHAH,3 J.B. DRESSMAN,4 D.M. BARENDS5

1Pharmacy Department, Chemical Sciences Faculty, National University of Córdoba, Córdoba, Argentina
2College of Pharmacy, University of Michigan, Ann Arbor, Michigan
3International Pharmaceutical Federation FIP, Den Haag, The Netherlands
4Department of Pharmaceutical Technology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany
5RIMV, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

Received 8 June 2005; accepted 7 February 2006
Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.20615

ABSTRACT: Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing amitriptyline hydrochloride are reviewed. Its therapeutic uses, its pharmacokinetic properties, the possibility of excipient interactions and reported BE/bioavailability (BA) problems are also taken into consideration. Literature data indicates that amitriptyline hydrochloride is a highly permeable active pharmaceutical ingredient (API). Data on the solubility according to the current Biopharmaceutics Classification System (BCS) were not fully available and consequently amitriptyline hydrochloride could not be definitively assigned to either BCS Class I or BCS Class II. But all evidence taken together, a biowaiver can currently be recommended provided that IR tablets are formulated with excipients used in existing approved products and that the dissolution meets the criteria defined in the Guidances. © 2006 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 95:966–973, 2006

Keywords: amitriptyline hydrochloride; Biopharmaceutics Classification System (BCS); permeability; solubility; absorption; biowaiver

INTRODUCTION

A monograph based on literature data is presented on amitriptyline hydrochloride, with respect to its biopharmaceutical properties and the risk of waiving in vivo bioequivalence (BE) testing in the approval of new immediate release (IR) solid oral dosage forms containing this active pharma-aceutical ingredient (API), including both reformulated products and new, multisource drug products. The purpose and scope of this series of monographs were discussed previously.1 Briefly, the aims of the present study are to evaluate all pertinent data available from literature sources to assess the appropriateness of such a biowaiver from the biopharmaceutical point of view and also from the perspective of public health. The progress in this series can be followed at the FIP Website.2

Up to now, monographs have been published on acetaminophen (paracetamol),3 atenolol,1 chloroquine,4 ibuprofen,5 propranolol,1 ranitidine,6 and verapamil.1
EXPERIMENTAL

A search in the PubMed Central and Scirus was conducted using the keyword amitriptyline combined with: absolute, absorption, aqueous, bioavailability, permeability, pharmacokinetics, oral, and solubility. Whenever possible, original literature was consulted; data from secondary sources were included for completeness or when original literature could not be located.

GENERAL CHARACTERISTICS

Amitriptyline is an INN name. Its chemical name is 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-propyldimethylamine. The molecular weight and melting point of amitriptyline hydrochloride are 313.97 and 196–197°C, respectively. Its structure is shown in Figure 1.

Therapeutic Indication and Therapeutic Index

The major therapeutic indication for amitriptyline is for the treatment of depression, although it is also indicated for a number of nervous system related disorders.9 In the treatment of depression, amitriptyline hydrochloride is given by mouth initially in a daily dose of 75 mg. Thereafter, the dose may be gradually increased, if necessary, to 150 mg daily. Therapy may also be begun with a single dose of 50–100 mg, increased by 25 or 50 mg as necessary to a total of 150 mg daily. Doses of up to 200 mg daily and, occasionally, up to 300 mg daily have been used in severely depressed patients.10 Severe symptoms of overdosage have been described, including unconsciousness, convulsions and myoclonus, hyperreflexia, hypothermia, hypotension, metabolic acidosis, and respiratory and cardiac depression, with life-threatening cardiac arrhythmias that may recur some days after apparent recovery.10 No data are available on the dose that gave rise to these symptoms.

CHEMICAL PROPERTIES

Solubility

Amitriptyline hydrochloride is soluble 1:1 in water.11 The USP12 and the Ph. Eur.7 report this API to be “freely soluble in water”. Amitriptyline free base is practically insoluble in water and its solubility in 0.1 M sodium hydroxide at 24 ± 1°C was recorded as 1.1 × 10−2 mg/mL. More recently, its solubility at 25°C was measured, using both the acid-base titration method and the shake-flask method.14 Both methods gave 2.0 × 10−3 mg/mL.

Experimental measured values of the solubility at 37°C in different physiologically relevant pHs, as required by the different Guidances,15–17 were not found, but solubilities at 25°C were estimated from the solubility and pKa. Taking the lowest reported solubility at that temperature, that is, 2.0 × 10−3 mg/mL, and the pKa value at 25°C reported, that is, 9.45 (see below), the values of Table 1 were calculated, whereas the solubility in pH 1.2 was estimated from the solubility of 1:1, reported for amitriptyline hydrochloride.11

Several reports indicate the protonated form of amitriptyline to self-aggregate with a critical micelle concentration of 3.6 × 10−2 mol/L and an aggregation number of 7.18–20

Partition Coefficient

Amitriptyline is a highly lipophilic molecule having a log P (octanol/water, pH 7.4) of 3.0,11 while the intrinsic log P of the free base was reported as 5.04.21 Calculations using fragmentation methods based on atomic contributions to lipophilicity gave values of 4.42 and 4.85, respectively.22 Other workers reported a C log P of 4.85.23

Figure 1. Structure of amitriptyline hydrochloride.
The pKa of amitriptyline has been reported as: 9.424, 9.4 (24°C/C6),13 9.45 (25°C),14 and 9.31 (37°C).11

Available Strengths

The WHO recommended dose is 25 mg.25 IR solid dosage forms with marketing authorization (MA) in Argentina26 and in Germany (DE)27 have strengths of 10 mg up to 75 mg; in the USA, MAs have been given to tablet strengths up to 150 mg.28

Permeability

The permeability in Caco-2 cell monolayers was measured at a high and a low concentration, in two directions.23 Apparent Caco-2 permeability for apical to basolateral transport values reported for two concentrations were 2.10 × 10⁻¹⁰ cm/s and 1.73 × 10⁻⁹ cm/s, respectively. In the same study, the permeability of other APIs with a high fraction absorbed were also measured; all these APIs showed a permeability of approximately 10⁻⁹ cm/s or higher, indicating that amitriptyline is a high permeable API also.

DOSAGE FORM PERFORMANCE

Excipients

Excipients present in IR amitriptyline hydrochloride tablets with a MA in DE, Finland (FI), and The Netherlands (NL) are summarized in Table 2. In vivo comparisons of different formulations were not reported. Therapeutic inequivalence between brand-name drug products and FDA-approved generic drug products has not been reported34 and there have been no reports of bioinequivalence of IR tablets with a MA in Argentina.24

Dissolution

The USP 28 specification for Amitriptyline Hydrochloride Tablets is not less than 75% (Q) dissolved
Table 2. Excipients<sup>a</sup> Present in Amitriptyline Hydrochloride<sup>b</sup> IR Solid Oral Drug Products<sup>c</sup> with a Marketing Authorization (MA) in Germany (DE), Finland (FI), and The Netherlands (NL)

<table>
<thead>
<tr>
<th>Excipient</th>
<th>DE</th>
<th>FI</th>
<th>NL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acacia</td>
<td>(1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aluminium hydroxide</td>
<td>(2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beeswax</td>
<td>(1); NL (3, 4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>(1); FI (5, 6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium hydrogen phosphate</td>
<td>(2, 7–10); NL (11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium phosphate</td>
<td>(3, 4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium stearate</td>
<td>(12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carmellose sodium</td>
<td>(13)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carnauba wax</td>
<td>(1); FI (5, 6); NL (3, 4, 11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellulose</td>
<td>(8, 10, 13–16); FI (17); NL (3, 4, 11, 18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copovidone</td>
<td>FI (17); NL (18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Croscarmellose</td>
<td>(15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td>FI (17); NL (18)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crospovidone</td>
<td>(16)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dibutyl phthalate</td>
<td>NL (19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diethyl phthalate</td>
<td>NL (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disodium edetate</td>
<td>NL (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethylcellulose</td>
<td>NL (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gelatin</td>
<td>DE (12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose, liquid</td>
<td>DE (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glyceryl palmitostearate</td>
<td>NL (3, 4, 19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydroxypropylcellulose</td>
<td>NL (3, 4, 11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypromellose</td>
<td>(2, 7–9, 14, 15); NL (3, 4, 11, 19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactose</td>
<td>(1, 2, 7–9, 12–16); FI (5, 6, 17); NL (3, 11, 18–20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Macrogol</td>
<td>(2, 7–9, 12–15); FI (5, 6, 17); NL (3, 4, 18, 19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>(1, 2, 7–10, 13–16); FI (5, 6, 17); NL (3, 4, 11, 18–20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maize starch</td>
<td>(1, 2, 7–10, 12, 14); FI (5, 6, 17); NL (3, 4, 11, 18–19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maize starch, pregelatinised</td>
<td>DE (13)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylcellulose</td>
<td>NL (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polyethylene terephthalate</td>
<td>(1, 13); NL (19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Povidone</td>
<td>(1, 8, 10, 13); FI (5, 6); NL (3, 4, 19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shellac</td>
<td>DE (1); NL (3, 4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silica</td>
<td>(2, 7–9, 12, 13); FI (17); NL (11, 18, 20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>FI (6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>(1, 2, 7–9, 14); NL (3, 4, 19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Starch</td>
<td>NL (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Starch, pregelatinised</td>
<td>NL (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stearic acid</td>
<td>NL (11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sucrose</td>
<td>DE (1); FI (5, 6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Talc</td>
<td>DE (1, 12–14); NL (3, 4, 11, 19)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Amitriptylin-neuraxpharm<sup>®</sup> 10/-25/-50 Dragees.
2. Amitriptylin beta<sup>®</sup> 10 Filmtabletten.
3. Amitriptylinehydrochloride 10 mg, tabletten (MA holder: Katwijk Farma).
5. Triptyl<sup>®</sup> 10 mg tabletten.
6. Triptyl<sup>®</sup> 25/50 mg tabletten.
7. Amineurin<sup>®</sup> 10/-25 Filmtabletten.
8. Amineurin<sup>®</sup> 50 Filmtabletten.
10. Amitriptylin—CT 25–75 mg Tabletten.
11. Tryptizol, tabletten 10/25/50 mg.
12. Amitriptylin-RPh<sup>®</sup> 25 mg Filmtabletten.
13. Amitriptyline-neuraxpharm<sup>®</sup> 75/-100 Filmtabletten.
14. Novoprotect<sup>®</sup> 10/-25 mg Filmtabletten.
15. Saroten<sup>®</sup> Tabs 50 mg Filmtabletten.
16. Syneudon<sup>®</sup> 50 Tabletten.
17. Saroten 10/25/50 mg tabletten, kalvopäällysteinen.
19. Amitripyline HCl Gf 25 mg, omhuule tabletten.
20. Amitriptyline HCl, tabletten 10 mg (MA holder: Pharmethica).

Sources of data: DE: www.rote-liste.de; FI: www.nam.fi; NL: www.cbg-meb.nl.
<sup>a</sup>Colourants are not included.
<sup>b</sup>Drug products containing other APIs than Amitriptyline Hydrochloride are excluded.
<sup>c</sup>Excluded are dosage forms that are swallowed by the patient in liquid form, such as oral solution.
in 45 min in 900 mL 0.1 N HCl using the basket at 100 rpm. Results of comparative studies in vitro of different formulations were not reported.

**DISCUSSION**

**Solubility**

The FDA defines “highly soluble” over the pH range 1–7.5, while the EU and the recently revised WHO Guidelines limit the requirements to the pH range 1–6.8. It was recently suggested that the FDA should also redefine the solubility boundaries for BCS Class I to pH 1.2–6.8. At 25°C, all tablet strengths conform to the criterion of 250 mL for the dose/solubility ratio at pH 6.8 and below, see Table 1. At pH 7.5, the WHO recommended dose complies with this dose/solubility ratio criterion but higher tablet strengths do not. However, these data refer to 25°C, not at 37°C, as required by the Guidances. If amitriptyline hydrochloride, like most drug substances, has an endothermic heat of solution it is reasonable to assume that amitriptyline hydrochloride will exhibit higher solubility at 37°C. On the other hand, calculating solubility using the Henderson–Hasselbalch equation, are highly inaccurate and differences between the calculated solubility and the experimental value of up to a factor of 776 have been reported. In summary, experimental solubility data at the conditions specified by the BCS Guidances are lacking and no concrete conclusion can be drawn as to whether amitriptyline hydrochloride meets either the FDA or EU/WHO definition of “highly soluble.”

**Permeability**

According to the present FDA and EU BCS Guidances, an API is classified as “highly permeable” if the fraction absorbed is 90% or higher whereas the recently revised WHO Guidelines sets a lower limit of 85% absorbed. Amitriptyline hydrochloride fulfills both criteria. Both log P and Caco-2 permeability data support the classification of this API as “highly permeable.”

**Surrogate Techniques for In Vivo BE Testing**

For amitriptyline hydrochloride, it is unlikely that bioequivalence between two IR solid oral dosage forms would arise from differences in permeability produced by formulation differences, in view of its high and hence non-critical permeability. Bioequivalence between formulations, if any exists, would most probably be caused by differences in in vivo dissolution, which is expected to be the most critical parameter in the absorption process, at least in the neutral pH range. Consequently, for amitriptyline hydrochloride IR solid oral dosage forms, comparative in vitro dissolution testing as per BCS Guidances is an appropriate surrogate technique for in vivo BE testing. The dissolution test USP 28 for amitriptyline hydrochloride Tablets uses dilute hydrochloric acid as test medium. In view of the solubility characteristics of amitriptyline hydrochloride, this dissolution medium is likely to be less discriminating than testing at a pH of about 6.8.

**Risks with Respect to Excipient and/or Manufacturing Variations**

Table 2 shows that a wide variety of well-known excipients used in IR amitriptyline hydrochloride formulations with MAs in a number of countries. In contrast to some previously discussed APIs the “bioavailability committee” of the regulatory authorities of DE classified amitriptyline hydrochloride in 1998 as an API for which in vivo BE testing was required. So, at least for the MA’s granted in DE, it can be assumed that these drug products successfully passed an in vivo BE study versus the innovator’s drug product. The lack of reports of BA/BE problems supports the view that these common excipients will have no effect on the BE of a test drug product, as long as they are incorporated in amounts currently used in IR tablet formulations.

An indication of the amounts usually present in dosage forms for drug products with a MA in the USA can be obtained from the FDA Inactive Ingredients Database.

**Risk of Bioequivalence in Terms of Therapeutic Outcome**

The Argentine Health Authority classified amitriptyline hydrochloride as an intermediate health-risk drug, which means that eventual complications of the sickness and/or adverse reactions arising from plasma concentrations outside the therapeutic window of the drug are not necessarily serious, and are unlikely to compromise the integrity of the individuals or be life-threatening.
BCS Classification and Biowaiving

Amitriptyline hydrochloride is “highly permeable,” but, as solid solubility data are lacking, no definitive conclusion can be drawn as to whether amitriptyline hydrochloride is “highly soluble.” Until appropriate experimental data are available, amitriptyline hydrochloride must be regarded as lying at the interface of BCS Class I/II. Other workers reached the same conclusion.41 Still other workers classified amitriptyline hydrochloride as BCS Class I, but this classification was reached on the basis of calculated log \( P \) data, and took only the 25 mg tablet strength into account.22,29,42 Nevertheless, all available data suggest that, even if a limited solubility of this API at pH 7.5 at 37 \(^\circ\)C should exist, this will not be problematic in vivo because, owing to its high permeability, the major absorption occurs in the first portion of the small intestine where pH is below 7. Moreover, comparative in vitro dissolution testing at pH 6.8, as requested in the BCS Guidances,15–17 can be expected to detect any bioinequivalence caused by differences in in vivo dissolution.

CONCLUSION

Despite the relative uncertainty of the BCS classification for amitriptyline hydrochloride, a biowaiver is scientifically justifiable for this API, provided that the test product is formulated with the excipients shown in Table 2, in amounts currently used in IR tablet formulations39 and shows rapid in vitro dissolution, according to the criteria as defined in the BCS Guidances.15–17

ACKNOWLEDGMENTS

Gert Ensing, RIVM, is acknowledged for aggregating the excipient information into tabular format.

REFERENCES


41. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the
